A seven-m6A regulator-related CpG site-based prognostic signature for endometrial carcinoma

Abstract

Background Endometrial carcinoma (EC) has become a common gynecologic malignancy with a high mortality. The m 6 A regulators have been identified to be closely associated with multiple human cancers including EC. However, the CpG methylation signature related to m 6 A regulators in EC remains unclear.Method The methylation profiles of EC patients including cancer samples and adjacent normal samples were obtained from The Cancer Genome Atlas (TCGA) database. The CpG sites in 20 m 6 A regulators were identified. Univariate Cox regression and LASSO Cox regression analysis were used to screen key CpG sites which were located at m 6 A regulators and significantly related to the prognosis of EC. The predictive model for EC prognosis was constructed, and multivariate Cox regression analysis was applied to explore whether the risk score derived from the model could function as an independent signature for EC prognosis. Meanwhile, a nomogram model was constructed by combing the independent prognostic signatures for prediction of the long-term survival in EC patients.Results A total of 396 CpG sites located at 20 m 6 A regulators were identified. A specific predictive model for EC prognosis based on 7 optimal CpG sites was constructed, which presented good performance in prognosis prediction of EC patients. Moreover, risk score was determined to be an independent signature both in the training set and validation set. By bringing in three independent prognostic factors (age, risk score, and TNM stage), the nomogram was constructed and could effectively predict the 3-and 5-year survival rates of EC patients. ConclusionOur study suggested that the CpG sites located at m 6 A regulators might be considered as potential prognostic signatures for EC patients.

High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma

“…A recent study further reported a predictive model for OS consisting of age, clinical stage, pathological tissue grade, tumor size, and ethnicity [ 31 ]. A predictive nomogram for endometrial carcinoma combining long noncoding RNA expression profiles and m6A regulator-related CpG sites was also shown recently [ 32 , 33 ]. Here, we constructed a new prognostic nomogram using age, clinical stage, histologic grade, tumor invasion, histological type and S100A2 levels as indicators that can be used by physicians to improve the accuracy of identifying high-risk patients.…”

Construction of novel hypoxia-related gene model for prognosis and tumor microenvironment in endometrial carcinoma

“…Many facets of RNA metabolism were affected by the m6A alteration, including RNA processing, nuclear export, RNA translation, and decay ( 37 ). According to new findings, m6A methylation played a critical role in endometrial cancer through a variety of pathways and expanded the potential for early cancer detection and therapy ( 38 – 40 ).…”

Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer

“…These data suggest that FTO, RBM15, and YTHDF1 are critical in the progression and prognosis of endometrial cancer (82,97). Interestingly, Zhang et al found that CpG sites located at the m 6 A regulatory site may be considered a potential prognostic feature of endometrial cancer patients (98). In a more detailed study, 19 m 6 A RNA methylation regulators were abnormally expressed in endometrial carcinoma.…”